Krystal Biotech (NASDAQ:KRYS) Stock Gets Price Target Trim from TD Cowen

Krystal Biotech (NASDAQ:KRYS) had its price objective reduced by investment analysts at TD Cowen from $403.00 to $380.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s target price indicates a potential upside of 26.79% from the company’s current price.

Several other analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $361.00 price objective on shares of Krystal Biotech in a report on Thursday, October 15th. Bank of America lifted their price objective on Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 23rd. Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, The Goldman Sachs Group initiated coverage on Krystal Biotech in a research note on Thursday, September 24th. They set a “buy” rating and a $441.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $372.40.

Krystal Biotech Stock Performance

Shares of KRYS stock traded up $3.81 during trading on Tuesday, hitting $299.71. 97,516 shares of the company were exchanged, compared to its average volume of 327,465. The business’s 50-day simple moving average is $336.45 and its 200 day simple moving average is $308.70. Krystal Biotech has a twelve month low of $192.52 and a twelve month high of $382.54. The firm has a market capitalization of $8.87 billion, a price-to-earnings ratio of 37.38 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.26. The firm had revenue of $127.34 million for the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, equities analysts forecast that Krystal Biotech will post 7.33 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC lifted its stake in shares of Krystal Biotech by 27.3% in the third quarter. Signaturefd LLC now owns 168 shares of the company’s stock valued at $56,000 after buying an additional 36 shares during the period. Torray Investment Partners LLC grew its position in Krystal Biotech by 0.4% during the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after buying an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in Krystal Biotech by 0.9% during the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock worth $1,537,000 after buying an additional 53 shares in the last quarter. Hanseatic Management Services Inc. increased its stake in Krystal Biotech by 2.0% during the third quarter. Hanseatic Management Services Inc. now owns 3,183 shares of the company’s stock valued at $1,059,000 after acquiring an additional 63 shares during the period. Finally, Heritage Family Offices LLP bought a new position in Krystal Biotech during the third quarter valued at about $25,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter EPS of $2.05, exceeding consensus estimates ranging from $1.79 to $1.92, while revenue of $127.34 million also topped expectations. The results were supported by continued demand for Vyjuvek. Earnings Beat May Change The Case For Krystal Biotech Stock
• Positive Sentiment: Management authorized a $400 million share-repurchase program over two years. Buybacks could support earnings per share and provide near-term demand for the stock. Krystal Biotech’s $400 Million Buyback
• Positive Sentiment: Analysts and market commentary highlighted Vyjuvek’s commercial strength, revenue growth and the possibility that the earnings beat could improve the investment outlook. Krystal Biotech Beats on Vyjuvek Strength
• Neutral Sentiment: Krystal revised its 2026 non-GAAP operating-expense outlook to $155 million–$165 million, reflecting continued investment in its clinical portfolio. Krystal Outlines $400 Million Share Repurchase
• Negative Sentiment: Third-quarter profit declined from the prior year despite the earnings beat, raising concerns about growth quality and the sustainability of profitability. Krystal’s Q3 Profit Declines
• Negative Sentiment: Timelines for parts of Krystal’s development pipeline slipped into 2027, delaying potential catalysts and contributing to investor disappointment. The buyback also creates an opportunity-cost and funding-risk debate while the company continues investing in clinical programs. Krystal Biotech Stock Stays Above Fair Value After Buyback Plan
• Negative Sentiment: With KRYS trading above some estimates of fair value and below its recent highs, investors appear to be demanding stronger forward growth to justify the valuation. Is Krystal Biotech Undervalued?

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.